The end-of-phase 2 (EOP2) meeting with FDA is a critical milestone in your development program and likely the most important interaction you will have with the Agency. Getting the most from this meeting can help successfully launch your phase 3 program and help you begin preparing for your marketing application (NDA/BLA) submission.

This webinar will cover:

• Goals for your EOP2 meeting
• What does it mean to be phase 3 ready?
• Developing the right questions to obtain clarity from FDA
• Timing considerations
• Common themes in FDA feedback
• Companies nearing completion of their phase 2 studies or who are planning phase 3 programs will benefit from attending this webinar.

Register here.